[Market Focus] AJU IB Investment Soars 30% on Hopes for Investment Returns
The stock price of AJU IB Investment, a venture capital (VC) firm, surged on heightened expectations for global bio investment returns.
As of 10:03 a.m. on February 27, AJU IB Investment was trading at 5,810 won, up 1,340 won (29.98%) from the previous day.
According to foreign media reports the previous day, global pharmaceutical company Gilead has agreed to acquire Axcella Therapeutics, a bio company invested in by Solasta Ventures, for 7.8 billion dollars (about 10 trillion won). Axcella Therapeutics is a company invested in by Solasta Ventures, the U.S. subsidiary of AJU IB Investment.
Hot Picks Today
"I Ate It Often Because It Tasted Good"... This Eating Habit Linked to 40% Higher Odds of Asymptomatic Cerebrovascular Damage
- "A College Degree Isn't Really Necessary"... Choi Taewon's Advice to Young People
- "My Stomach Was in Knots All Night After Eating a Hamburger"... Woman's Surprise Diagnosis After Tests Came Back Normal
- “Dad Just Gave It to Us as a Gift”... Scratched a Lottery Ticket at a Family Gathering and Hit a 1 Billion Won Jackpot
- "What Is That Disgusting Lump in the Water?"... Bizarre Organism Found in Bukhan River
AJU IB Investment has been divesting from Axcella Therapeutics since its listing on the NASDAQ in 2023 and into last year. It is known that the company still holds a significant portion of shares. AJU IB Investment expects an investment multiple of up to 9 times its original principal.
![[Market Focus] AJU IB Investment Soars 30% on Hopes for Investment Returns](http://www.asiae.co.kr/news/img_view.htm?img=2026022709360655459_1772152566.jpg)
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
!["Please Take Them Off!" They Made It All the Way to the Bed... Then "80% of Fecal Bacteria" Struck [Deep Scroll]](https://cwcontent.asiae.co.kr/asiaresize/307/2026101610053063338_1792112730.png)
